EG

Analyst Note: EG (Everest Re Group, Ltd.)

Date: 2026-06-13 Price: $335.63

1. Structural Readiness

• State: Forming
• Conservative Entry: Not yet defined (awaiting confirmed breakout).
• Aggressive/Pre-Breakout Entry: Current price ($335.63) represents a partial entry signal for a forming coil, acknowledging the ~69% historical probability of a breakout from this structure, but it is not a confirmed actionable setup on its own.
• Breakout Level: Not yet established (requires price to close above the resistance formed by the coil).
• Current Price: $335.63.
• Extension: Not applicable (price has not yet extended from a confirmed breakout).
• ATR Context: Current ATR is 2.3% (sub-threshold). This indicates lower volatility than the historical "sweet spot" (4–6%), suggesting the market is currently in a consolidation or waiting phase rather than a high-momentum expansion.

2. Thesis Layer

This is a TACTICAL, setup-led name. There is NO named secular thesis attached to this setup at this date. The investment case is not derived from a macro secular trend (e.g., "AI infrastructure boom" or "climate change hedge") but is judged strictly on the quality of the structural setup (the forming coil) and the immediate business fundamentals disclosed by management. The conviction relies on the execution of the company's specific capital allocation and portfolio rotation strategy rather than a broad market tailwind.

3. Business Overview

Everest Re Group, Ltd. is a global provider of reinsurance and insurance solutions, operating across the U.S., Bermuda, and international regions. As of the latest reporting period (FY 2025), the company operates with a gross written premium (GWP) of $17.7 billion.

Key Business Segments & Recent Structural Changes:

• Segment Realignment: Effective January 1, 2026, the company reorganized its reportable segments from "Reinsurance and Insurance" to Reinsurance Treaty, Global Wholesale & Specialty, and Legacy. This change followed the sale of renewal rights for the Commercial Retail Insurance business to AIG (E8, E19).
• Portfolio Rotation: The company has actively rotated its portfolio toward short-tail and specialty lines. Treaty Reinsurance delivered an 87.2% combined ratio for the quarter, generating $315 million in underwriting income (E6, E7).
• Capital Release & Divestitures:
• AIG Transaction: Sold renewal rights for certain commercial retail lines (U.S., U.K., Asia Pacific) for $252 million, covering an estimated $2 billion in aggregate GWP (E19, E20).
• Canadian Exit: Entered a purchase agreement on March 22, 2026, to sell Everest Canada (Canadian Commercial Retail Insurance) for C$410 million. The transaction is anticipated to close in the second half of 2026 (E9, E10).
• Adverse Development Reinsurance: Entered agreements effective October 1, 2025, to reinsure potential adverse loss development for accident years 2024 and prior up to a $1.2 billion limit, transferring $1.25 billion in reserves (E13, E14, E15).
• Capital Allocation: Management is raising the quarterly share repurchase floor from $200 million to $300 million, absent major external dislocation (E5).
• Mt. Logan: The captive insurance subsidiary continues to grow, with assets under management exceeding $2.6 billion (E3).

4. Archetype and Conviction Analysis

Archetype: Margin Inflector. Fit: The setup fits the "Margin Inflector" archetype because the company is actively reducing exposure to long-tail, volatile casualty lines (reducing casualty premium by >$1.2 billion since Jan 2024) and replacing them with higher-yield, short-tail specialty lines. The adverse development reinsurance deal and the sale of the Canadian and U.S. retail operations are structural moves designed to clean up the balance sheet and release capital, directly inflecting the margin profile.

Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and execution-dependent. The "Margin Inflector" narrative is strong based on the 87.2% combined ratio in Treaty Reinsurance and the explicit reduction of casualty exposure.
• Evidence Quality: High. The evidence base is robust, citing specific earnings transcripts (April 2026) and SEC filings (May 2026) with concrete figures (e.g., $315M income, $1.2B premium reduction, $2.6B AUM).
• Structural Quality: Strong. The balance sheet is being actively managed ($15.5B equity, $62.5B assets). The broker concentration (Marsh McLennan 22.4%, Aon 18.7%) is a known risk but is standard for the industry (E18).
• Rerating Potential: Moderate to High. The market may re-rate the stock as the "meaningful capital release" from the Canadian transaction becomes visible in the back half of 2026 (E4) and as the share repurchase program scales to $300M/quarter.

Valuation Context: Forward consensus EPS is projected at $52.13 for FY1 and $60.66 for FY2 (E33). At a current price of $335.63, the stock trades at approximately 6.4x FY1 EPS and 5.5x FY2 EPS. This valuation compression relative to the projected earnings growth suggests the market is currently pricing in the execution risk of the divestitures and the softening property catastrophe pricing (down 13% globally) (E2).

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Confirmation of the Canadian transaction closing in the second half of 2026 as anticipated.
• Sustained combined ratios below 90% in the Global Wholesale & Specialty segment.
• A confirmed price breakout above the forming coil resistance level, accompanied by an increase in ATR (moving from sub-threshold to the 4–6% sweet spot).

What Would Invalidate the Case:

• A significant deterioration in the property catastrophe pricing environment beyond the current 13% softening, leading to a spike in loss ratios.
• Failure to execute the capital release or repurchase program due to "major external dislocation."

Gaps in Evidence:

• Immediate Catalyst Timing: While management expects capital release in the "back half of 2026," the exact timing of the Canadian deal closing is subject to regulatory approvals (E10), creating a timing gap for the capital release.
• Detailed Broker Concentration Risk: While the top brokers are listed, the specific impact of a potential loss of Marsh McLennan or Aon business is not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Treaty Reinsurance generated $315 million income on an 87.2% combined ratio; Management raised quarterly buyback floor to $300 million; Portfolio rotation to short-tail lines and $1.2B casualty premium reduction since Jan 2024. Key risks: Property catastrophe pricing continues to soften (down 13% globally); Canadian divestiture closing is contingent on regulatory approvals in H2 2026; Sub-threshold ATR (2.3%) indicates low volatility and potential for extended consolidation. Sizing hint: Position size should reflect the "forming" nature of the setup; allocate capital that can withstand a potential wait for the breakout confirmation without over-concentration. Expected path: Management expects meaningful capital release to become visible in H2 2026; share repurchases will likely support the floor; price action should consolidate before a potential expansion if the 87.2% combined ratio holds. Expected horizon: 6 to 12 months, aligning with the anticipated closing of the Canadian transaction and the visibility of capital release.